AstraZeneca’s asthma drug fails main goal of COPD study

(Reuters) -AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich)